Filters
| Tests names and labs | Conditions | Genes, analytes, and microbes | Methods |
|---|---|---|---|
Fulgent Genetics United States | 505 | 132 |
|
Fulgent Genetics United States | 133 | 56 |
|
Fulgent Genetics United States | 533 | 149 |
|
Spinocerebellar Ataxia Type 14: gene sequencing CEN4GEN Institute for Genomics and Molecular Diagnostics Canada | 1 | 1 |
|
SPINOCEREBELLAR ATAXIA (AUTOSOMAL DOMINANT) (SCAs) Laboratorio de Genetica Clinica SL Spain | 18 | 19 |
|
Ataxia, Complete Dominant Evaluation Athena Diagnostics United States | 31 | 25 |
|
Ataxia, Supplemental Dominant Evaluation Athena Diagnostics United States | 22 | 16 |
|
Ataxia, Comprehensive Evaluation Athena Diagnostics United States | 44 | 42 |
|
Asper Biogene Asper Biogene LLC Estonia | 180 | 139 |
|
CeGaT GmbH Germany | 1 | 1 |
|
Spinocerebellar ataxia type 14 Bioarray Spain | 1 | 1 |
|
Ataxia and differential diagnoses Panel CeGaT GmbH Germany | 173 | 204 |
|
Fulgent Genetics United States | 1 | 1 |
|
Fulgent Genetics United States | 5128 | 4672 |
|
Genome Diagnostics Laboratory University Medical Center Utrecht Netherlands | 23 | 16 |
|
Retinitis Pigmentosa NGS Panel Fulgent Genetics United States | 329 | 124 |
|
Baylor Genetics United States | 842 | 637 |
|
MedGene Slovakia | 1 | 1 |
|
MedGene Slovakia | 1 | 1 |
|
Comprehensive Eye Disorders NGS Panel Fulgent Genetics United States | 1018 | 459 |
|
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.